Compare TG Therapeutics Inc (TGTX) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Trade Desk Inc — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.36B), while Trade Desk Inc trades at $13.91 (market cap $6.52B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals.
| TGTX | TTD | |
|---|---|---|
Market Cap | $8.36B | $6.52B |
Sector | Health | Technology |
52-Week High | $59.06 | $54.13 |
52-Week Low | $26.94 | $13.03 |
Enterprise Value | $8.57B | $5.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The stock shows strong profitability with a net income margin of 55.22% and ROE of 100.28%, though recent quarters have seen earnings misses. Revenue growth is robust, with 2026 guidance raised to $950 million for BRIUMVI, and buyout rumors have fueled positive sentiment.
The outlook for TGTX is positive driven by BRIUMVI's commercial success and pipeline catalysts, but risks include earnings volatility, high valuation multiples, and competitive pressures. Institutional accumulation supports upside, yet investors should weigh execution risks against growth potential.
The Trade Desk (TTD) trades at $14.02, down 2.84% on the day and near its 52-week lows, reflecting significant year-to-date pressure. Recent financials show revenue growth slowing to 3% in Q2 2026 with earnings misses, while the company undergoes a 15% workforce restructuring. Technical indicators signal a bearish trend with mixed momentum oscillators. Despite strong profitability margins, valuation multiples remain compressed amid weak advertising demand and competitive pressures.
Outlook remains cautious with near-term headwinds from soft ad spending and execution risks from restructuring. Long-term opportunities exist in CTV and AI-driven ad platforms, but investor sentiment is divided with analysts showing mixed ratings. The stock trades below consensus price targets, offering potential upside if operational improvements materialize, though volatility may persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
